Company of the Week: Braveheart Bio
With a name like Braveheart, this San Francisco-based biotech is showing plenty of heart (and courage) as it launches into
The Geopolitical Royalty: Structuring and De-risking Cross-Border Biotech Revenue Streams Between China and the West
A New Axis of Royalty Flows
China's biotech industry has become an increasingly vital node in global pharmaceutical
From Ivory Tower to Wall Street: Monetizing University Biotech Royalties
A scientist in a university lab toils over a breakthrough therapy. Years later, that discovery becomes a best-selling drug, delivering
Navigating Regulatory and Reimbursement Disruption: How Accelerated Approvals and Pricing Reforms Are Reshaping Pharmaceutical Royalty Valuations
Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty
The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory
The Weekly Term Sheet (45)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Return of Royalty
On 19 November, as the Jefferies London Healthcare Conference closes for the day, a different conversation begins. Registration for our
Fund of the Week: Lilly Ventures – Eli Lilly's Strategic Biotech Investor
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the week: Hemab Therapeutics
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Multiple Royalty Streams on a Single Drug: Practical Realities
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalty Stream Sales and Buybacks in Pharma Financing
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
